Elimination of latently HIV-infected cells from antiretroviral therapy-suppressed subjects by engineered immune-mobilizing T-cell receptors

Molecular Therapy

Volumn 24, Issue 11, 2016, Pages 1913-1925

  Yang, Hongbing ^a   Buisson, Sandrine ^b   Bossi, Giovanna ^b   Wallace, Zoe ^a   Hancock, Gemma ^a   So, Chun ^a   Ashfield, Rebecca ^b   Vuidepot, Annelise ^b   Mahon, Tara ^b   Molloy, Peter ^b   Oates, Joanne ^b   Paston, Samantha J ^b   Aleksic, Milos ^b   Hassan, Namir J ^b   Jakobsen, Bent K ^b   Dorrell, Lucy ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Immunocore Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID DERIVATIVE; ANTIRETROVIRUS AGENT; BISPECIFIC ANTIBODY; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; GAG PROTEIN; HLA A ANTIGEN; IMMUNEMOBILIZING MONOCLONAL T CELL RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; SERYLLEUCYLTYROSYLASPARAGYLTHREONYLVALYLALANYLTHREONYLLEUCINE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ARTICLE; BIOENGINEERING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SYNTHESIS; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LATENT VIRUS INFECTION; NONHUMAN; PROTEIN EXPRESSION; VIRAL CLEARANCE; VIRUS CELL INTERACTION; VIRUS REACTIVATION; CELL LINE; DRUG EFFECTS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; PHYSIOLOGY; VIROLOGY; VIRUS LATENCY;

ANTIBODIES, MONOCLONAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; RECEPTORS, ANTIGEN, T-CELL; VIRUS LATENCY;

EID: 84978064551     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2016.114     Document Type: Article

References (59)

1. Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, et al. (2011). Evidence for the cure of HIV infection by CCR5?32/?32 stem cell transplantation. Blood 117: 2791-2799.
2. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, et al. (2012). Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36: 491-501.
3. Autran B, Descours, B, and Bacchus C. (2013). Immune control of HIV-1 reservoirs. Curr Opin HIV AIDS 8: 204-210.
4. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al. (2012). Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487: 482-485.
5. Vanham, G, and Van Gulck E. (2012). Can immunotherapy be useful as a functional cure for infection with Human Immunodeficiency Virus-1? Retrovirology 9: 72.
6. Bullen CK, Laird GM, Durand CM, Siliciano, JD, and Siliciano RF. (2014). New ex vivo approaches distinguish effective, and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 20: 425-429.
7. Dorrell L, Yang H, Ondondo B, Dong T, di Gleria K, Suttill A, et al. (2006). Expansion, and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine. J Virol 80: 4705-4716.
8. Yang H, Dong T, Turnbull E, Ranasinghe S, Ondondo B, Goonetilleke N, et al. (2007). Broad TCR usage in functional HIV-1-specific CD8+ T cell expansions driven by vaccination during highly active antiretroviral therapy. J Immunol 179: 597-606.
9. Autran B, Murphy RL, Costagliola D, Tubiana R, Clotet B, Gatell J, et al. ORVACS Study Group. (2008). Greater viral rebound, and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS 22: 1313-1322.
10. Schooley RT, Spritzler J, Wang H, Lederman MM, Havlir D, Kuritzkes DR, et al. AIDS Clinical Trials Group 5197 Study Team. (2010). AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replicationdeficient adenovirus type 5 vaccine expressing the HIV-1 core protein. J Infect Dis 202: 705-716.
11. Casazza JP, Bowman KA, Adzaku S, Smith EC, Enama ME, Bailer RT, et al. VRC 101 Study Team. (2013). Therapeutic vaccination expand s, and improves the function of the HIV-specific memory T-cell repertoire. J Infect Dis 207: 1829-1840.
12. Pollard RB, Rockstroh JK, Pantaleo G, Asmuth DM, Peters B, Lazzarin A, et al. (2014). Safety, and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 rand omised, double-blind, placebo-controlled trial. Lancet Infect Dis 14: 291-300.
13. Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, et al. (2006). Monoculturederived T lymphocytes specific for multiple viruses expand, and produce clinically relevant effects in immunocompromised individuals. Nat Med 12: 1160-1166.
14. Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, et al. (2013). Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 121: 5113-5123.
15. Lam S, Sung J, Cruz C, Castillo-Caro P, Ngo M, Garrido C, et al. (2015). Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expand ed from HIV+ patients: implications for immunotherapy. Mol Ther 23: 387-395.
16. Sung JA, Lam S, Garrido C, Archin N, Rooney CM, Bollard CM, et al. (2015). Expand ed cytotoxic T-cell lymphocytes target the latent HIV reservoir. J Infect Dis 212: 258-263.
17. Kershaw MH, Westwood, JA, and Darcy PK. (2013). Gene-engineered T cells for cancer therapy. Nat Rev Cancer 13: 525-541.
18. Mitsuyasu RT, Anton PA, Deeks SG, Scadden DT, Connick E, Downs MT, et al. (2000). Prolonged survival, and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+), and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 96: 785-793.
19. Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, et al. (2012). Decade-long safety, and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 4: 132ra53.
20. Varela-Rohena A, Molloy PE, Dunn SM, Li Y, Suhoski MM, Carroll RG, et al. (2008). Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med 14: 1390-1395.
21. Joseph A, Zheng JH, Follenzi A, Dilorenzo T, Sango K, Hyman J, et al. (2008). Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro, and in vivo HIV-1-specific inhibitory activity. J Virol 82: 3078-3089.
22. Kitchen SG, Levin BR, Bristol G, Rezek V, Kim S, Aguilera-Sand oval C, et al. (2012). In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells. PLoS Pathog 8: e1002649.
23. Schwartz O, Marechal V, Le Gall S, Lemonnier, F, and Heard JM. (1996). Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 2: 338-342.
24. Rajapaksa US, Li D, Peng YC, McMichael AJ, Dong, T, and Xu XN. (2012). HLA-B may be more protective against HIV-1 than HLA-A because it resists negative regulatory factor (Nef) mediated down-regulation. Proc Natl Acad Sci USA 109: 13353-13358.
25. Deng K, Pertea M, Rongvaux A, Wang L, Durand CM, Ghiaur G, et al. (2015). Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517: 381-385.
26. Liddy N, Bossi G, Adams KJ, Lissina A, Mahon TM, Hassan NJ, et al. (2012). Monoclonal TCR-redirected tumor cell killing. Nat Med 18: 980-987.
27. McCormack E, Adams KJ, Hassan NJ, Kotian A, Lissin NM, Sami M, et al. (2013). Bi-specific TCR-Anti CD3 redirected T-cell targeting of NY-ESO-1-, and LAGE-1-positive tumors. Cancer Immunol Immunother 62: 773-785.
28. Middleton M, Evans J, Steven N, Corrie P, Mulatero C, Sznol, M, et al. (2014). IMCgp100: a novel bispecific biologic for the treatment of malignant melanoma 105th Annu. Meet. Am. Assoc. Cancer Res, San Diego, California: p CT329.
29. Bossi G, Buisson S, Oates J, Jakobsen, BK, and Hassan NJ. (2014). ImmTAC-redirected tumor cell killing induces, and potentiates antigen cross-presentation by dendritic cells. Cancer Immunol Immunother 63: 437-448.
30. Middleton M, Corrie P, Sznol M, Infante J, Mulatero C, Evans, J, et al. (2015) A phase I/IIa study of IMCgp100: Partial, and complete durable responses with a novel first-in-class immunotherapy for advanced melanoma. Proc. 106th Annu. Meet. Am. Assoc. Cancer Res, Philadelphia: p CT106.
31. Przepiorka D Ko CW, Deisseroth A, Yancey CL, Cand au-Chacon R, Chiu HJ, et al. (2015). FDA Approval: Blinatumomab. Clin Cancer Res 21: 4035-4039.
32. Purbhoo MA, Sutton DH, Brewer JE, Mullings RE, Hill ME, Mahon TM, et al. (2006). Quantifying, and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors. J Immunol 176: 7308-7316.
33. Bossi G, Gerry AB, Paston SJ, Sutton DH, Hassan, NJ, and Jakobsen BK. (2013). Examining the presentation of tumor-Associated antigens on peptide-pulsed T2 cells. Oncoimmunology 2: e26840.
34. Yang H, Yorke E, Hancock G, Clutton G, Sand e N, Angus B, et al. (2013). Improved quantification of HIV-1-infected CD4+ T cells using an optimised method of intracellular HIV-1 gag p24 antigen detection. J Immunol Methods 391: 174-178.
35. Spina CA, and erson J, Archin NM, Bosque A, Chan J, Famiglietti M, et al. (2013). An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems, and resting CD4+ T cells from aviremic patients. PLoS Pathog 9: e1003834.
36. Migueles SA, Weeks KA, Nou E, Berkley AM, Rood JE, Osborne CM, et al. (2009). Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. J Virol 83: 11876-11889.
37. Eriksson EM, Milush JM Ho EL, Batista MD, Holditch SJ, Keh CE, et al. (2012). Expansion of CD8+ T cells lacking Sema4D/CD100 during HIV-1 infection identifies a subset of T cells with decreased functional capacity. Blood 119: 745-755.
38. Vinikoor MJ, Cope A, Gay CL, Ferrari G, McGee KS, Kuruc JD, et al. (2013). Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation. J Acquir Immune Defic Syndr 62: 505-508.
39. Thornberry, NA, and Lazebnik Y. (1998). Caspases: enemies within. Sci 281: 1312-1316.
40. de Oliveira Pinto LM, Lecoeur H, Ledru E, Rapp C, Patey, O, and Gougeon ML. (2002). Lack of control of T cell apoptosis under HAART. Influence of therapy regimen in vivo, and in vitro. AIDS 16: 329-339.
41. Wang FX, Xu Y, Sullivan J, Souder E, Argyris EG, Acheampong EA, et al. (2005). IL-7 is a potent, and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 115: 128-137.
42. Cillo AR, Sobolewski MD, Bosch RJ, Fyne E, Piatak, M Jr, Coffin JM, et al. (2014). Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 111: 7078-7083.
43. Graf EH, Pace MJ, Peterson BA, Lynch LJ, Chukwulebe SB, Mexas AM, et al. (2013). Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance in vitro, and can be detected in vivo [corrected]. PLoS One 8: e71879.
44. Sung JA, Pickeral J, Liu L, Stanfield-Oakley SA, Lam CY, Garrido C, et al. (2015). Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. J Clin Invest 125: 4077-4090.
45. Gray CM, Lawrence J, Schapiro JM, Altman JD, Winters MA, Crompton M, et al. (1999). Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). J Immunol 162: 1780-1788.
46. Buckheit, RW 3rd, Salgado M, Silciano, RF, and Blankson JN. (2012). Inhibitory potential of subpopulations of CD8+ T cells in HIV-1-infected elite suppressors. J Virol 86: 13679-13688.
47. Rehr M, Cahenzli J, Haas A, Price DA, Gostick E, Huber M, et al. (2008). Emergence of polyfunctional CD8+ T cells after prolonged suppression of human immunodeficiency virus replication by antiretroviral therapy. J Virol 82: 3391-3404.
48. Kassu A, Marcus, RA, D?Souza MB, Kelly-McKnight, EA, and Palmer BE. (2011). Suppression of HIV replication by antiretroviral therapy reduces TIM-3 expression on HIV-specific CD8(+) T cells. AIDS Res Hum Retroviruses 27: 1-3.
49. Stevenson M, Stanwick TL, Dempsey, MP, and Lamonica CA. (1990). HIV-1 replication is controlled at the level of T cell activation, and proviral integration. EMBO J 9: 1551-1560.
50. Pace MJ, Graf EH, Agosto LM, Mexas AM, Male F, Brady T, et al. (2012). Directly infected resting CD4+T cells can produce HIV Gag without spreading infection in a model of HIV latency. PLoS Pathog 8: e1002818.
51. Buckheit, RW 3rd, Siliciano, RF, and Blankson JN. (2013). Primary CD8+ T cells from elite suppressors effectively eliminate non-productively HIV-1 infected resting, and activated CD4+ T cells. Retrovirol 10: 68.
52. Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, et al. (2013). Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med 5: 197ra103.
53. Oates J, Hassan, NJ, and Jakobsen BK. (2015). ImmTACs for targeted cancer therapy: Why, what, how, and which. Mol Immunol 67: 67-74.
54. Li Q, Skinner PJ Ha SJ, Duan L, Mattila TL, Hage A, et al. (2009). Visualizing antigen-specific, and infected cells in situ predicts outcomes in early viral infection. Sci 323: 1726-1729.
55. Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, et al. (2013). Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog 9: e1003174.
56. Hong JJ, Amancha PK, Rogers K, Ansari, AA, and Villinger F. (2012). Spatial alterations between CD4(+) T follicular helper B, and CD8(+) T cells during simian immunodeficiency virus infection: T/B cell homeostasis, activation, and potential mechanism for viral escape. J Immunol 188: 3247-3256.
57. Fukazawa Y, Lum R, Okoye AA, Park H, Matsuda K, Bae JY, et al. (2015). B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat Med 21: 132-139.
58. Li Y, Moysey R, Molloy PE, Vuidepot AL, Mahon T, Baston E, et al. (2005). Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol 23: 349-354.
59. Yang H, Wu H, Hancock G, Clutton G, Sand e N, Xu X, et al. (2012). Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. J Infect Dis 206: 552-561.